First Header Logo Second Header Logo

Connection

Timothy Pardee to DNA Damage

This is a "connection" page, showing publications Timothy Pardee has written about DNA Damage.
Connection Strength

0.460
  1. Alexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TS. The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. PLoS One. 2017; 12(6):e0179798.
    View in: PubMed
    Score: 0.141
  2. Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.
    View in: PubMed
    Score: 0.118
  3. Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014 Jan; 93(1):47-55.
    View in: PubMed
    Score: 0.110
  4. Pardee TS, Zuber J, Lowe SW. Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Exp Hematol. 2011 Apr; 39(4):473-485.e4.
    View in: PubMed
    Score: 0.091
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.